Invigo advised Boehringer Ingelheim International GmbH on a new collaboration and license agreement with respect to the outlicensing of certain indications of a Boehringer Ingelheim compound.  The compound will be further developed by the French company Aurobac Therapeutics SAS under the agreement for the treatment of septic shock, in collaboration with Boehringer Ingelheim.

Read more about this topic and Aurobac Therapeutics on Boehringer Ingelheim’s website: AUROBAC’s Strategy & Pipeline Against Severe Infections & Resistance | Boehringer Ingelheim